ized phase II trial on metastatic melanoma revealed significant impact of pioglitazone, a peroxisome proliferator-activated receptor c (PPAR c ) 3, 4 agonist, on inflammation control, progression-free survival and overall survival when added to immunemodulatory and angiostatic acting metronomic low-dose chemotherapy. [5] [6] [7] In the present phase I trial we studied tolerability and efficacy of the original combination pioglitazone daily 60 mg p.o, etoricoxib daily 60 mg p.o., plus low-dose trofosfamide daily 50 mg three times p.o., and supplemented temsirolimus i.v. weekly at two dose levels, cohort 1, 15 mg, cohort 2, 25 mg (PETT schedule) (Fig. 1) . 8, 9 All medications were given continuously from day 1 until progression. Main inclusion criteria were age >18 years, histologically diagnosed metastatic melanoma with BRAF (the human gene that codes for the serine/threonine protein kinase B-Raf) wildtype, and LDH level >0.8 ULN, measurable lesions, and subjects had to receive study medication as first-line therapy.
Dose-limiting toxicity (DLT) was defined as any toxicity within the first 3 weeks of treatment with CTCAE (NCI-CTCAE version 4.0) grade ≥3 and a causal relationship to the administration of one of the study drugs. At the end of phase I, patients were followed according RECIST criteria for progression-free and overall survival. Computed tomography or magnetic resonance imaging (RECIST criteria) was performed every 8 weeks. The trial is approved by the local ethic committee and registered at ClinicalTrials.gov (NCT01614301).
Six elderly female patients (68-86 years old) with stage IV melanoma of uveal (n = 2) or cutaneous origin (n = 4), diffuse and multifocal liver metastases (n = 4) or tumour growth per continuitatem (n = 2) were enrolled during phase I. Local pretreatment and metastatic sites at study inclusion are listed in Table 1 .
The 25 mg dose of temsirolimus was chosen for the randomized phase II part of the study as no DLTs occurred in cohort 1 or 2. Two severe adverse events (SAEs) were observed during phase I part of the study, one due to pneumonia and another to pleural effusion. Both SAEs resolved during continuation of study medication. Grade 3 (no grade 4) toxicities during the follow-up phase are listed in Table 1 . According to scheduled dose reductions, trofosfamide was reduced to 50 mg twice daily in four patients. Due to oedema, the dose of pioglitazone was reduced to 30 mg daily in two patients.
Progression-free survival was 4-13 months, with four disease stabilizations, one mixed response (no objective response in the radiation field) and one partial response (PR) ( Table 1) . One stable disease in a patient with diffuse as well as measurable liver metastases of uveal melanoma was associated with a steep decline of melanoma inhibitory activity (MIA) and an improvement of Eastern Cooperative Oncology Group (ECOG )status from ECOG 2 to 1 (Fig. 1, Table 1 ). PR was not associated with a significant decline of MIA (Table 1) . Interestingly, two patients with extensive metastatic liver involvement from uveal melanoma had a comparatively long progression-free survival.
In all patients, progression took place at the original metastatic sites. Patients, who were prior irradiated, presented with progression in the radiation field. To our knowledge, this is the first report describing the use of PETT schedule, to successfully control both, metastatic growth in cutaneous and uveal melanoma by simultaneously targeting multiple hallmarks of melanoma: Communicative reprogramming may overcome (molecular-)genetic heterogeneity among melanomas of quite different origin as well as at different metastatic sites. 2, 5 PETT schedule provides a modest toxicity profile and omits maximal tolerable dosages of single drugs by concertedly modulating melanoma plus adjacent stroma cell functions. 3, 5, 8, 10 These promising data with PETT combination therapy are currently studied in a randomized phase II trial in second-line. A.R., C.H. designed the research, analysed the data and wrote the paper; C.H., M.V., Ch.H., M.L., M.B., S.H. and A.R. treated the patients; W.H. critically reviewed the manuscript. 
